A prognostic classification system for uveal melanoma based on a combination of patient age and sex, the American Joint Committee on Cancer and the Cancer Genome Atlas models

Gill, Viktor Torgny; Sabazade, Shiva; Herrspiegel, Christina; Ewens, Kathryn G.; Opalko, Adrianna; Dan, Nicole; Christersdottir, Tinna; Rendahl, Alexander Berg; Shields, Carol L.; Seregard, Stefan; Ganguly, Arupa; Stålhammar, Gustav

doi:10.1111/aos.15210

Cited by 13 publications

(7 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study also highlighted the statistical significance of ciliary body involvement (CBI) in prognosis. Concerning therapeutic implications, Gill VT. et al's study reported the absence of metastasis for the first favorable prognostic class, while Group 4 patients had a very high metastatic risk, and this may warrant inclusion in randomized trials with adjuvant treatment [49].…”

Section: Dogrusöz Et Al's 2017 Study On 522 Patients [45]mentioning

confidence: 95%

See 1 more Smart Citation

Pathological and Molecular Diagnosis of Uveal Melanoma

Păsărică,

Curcă,

Dragosloveanu

et al. 2024

Diagnostics

View full text Add to dashboard Cite

(1) Background: Uveal melanoma (UM) is a common malignant intraocular tumor that presents with significant genetic differences to cutaneous melanoma and has a high genetic burden in terms of prognosis. (2) Methods: A systematic literature search of several repositories on uveal melanoma diagnosis, prognosis, molecular analysis, and treatment was conducted. (3) Results: Recent genetic understanding of oncogene-initiation mutations in GNAQ, GNA11, PLCB4, and CYSLTR2 and secondary progression drivers of BAP1 inactivation and SF3B1 and EIF1AX mutations offers an appealing explanation to the high prognostic impact of adding genetic profiling to clinical UM classification. Genetic information could help better explain peculiarities in uveal melanoma, such as the low long-term survival despite effective primary tumor treatment, the overwhelming propensity to metastasize to the liver, and possibly therapeutic behaviors. (4) Conclusions: Understanding of uveal melanoma has improved step-by-step from histopathology to clinical classification to more recent genetic understanding of oncogenic initiation and progression.

show abstract

Section: Dogrusöz Et Al's 2017 Study On 522 Patients [45]mentioning

confidence: 95%

“…Gill VT. et al's 2023 study proposed the incorporation of an improved classification system based on patient age, gender, AJCC T-categories, and TCGA groups A to D [49]. This study also highlighted the statistical significance of ciliary body involvement (CBI) in prognosis.…”

Section: Dogrusöz Et Al's 2017 Study On 522 Patients [45]mentioning

confidence: 97%

Pathological and Molecular Diagnosis of Uveal Melanoma

Păsărică,

Curcă,

Dragosloveanu

et al. 2024

Diagnostics

View full text Add to dashboard Cite

show abstract

“…The TCGA project was established with the primary objective of comprehensively characterizing the molecular alterations inherent in cancer cells through the analysis of vast amounts of data acquired from numerous human samples. This ambitious initiative aimed to enhance our understanding of the intricate molecular landscape of cancer and provide valuable insights into the underlying mechanisms driving tumorigenesis and disease progression) [8,9,14,122] Abbreviations: BAP1 BRCA1 Associated Protein 1, SF3B1 Splicing Factor 3b Subunit 1, EIF1AX Eukaryotic Translation Initiation Factor 1A X-Linked to induce tolerance in homeostasis [126,127]. This fact along with other characteristics, makes the liver a favorable site for primary and metastatic tumor cells to grow.…”

Section: Role Of Immune System In Melanomamentioning

confidence: 99%

“…Prognostic indicators for UM include demographic, clinical, and histological characteristics, such as age, gender, tumor size, location, configuration, staging, and specific histopathological features [9][10][11]. In recent years, the role of genetics in prognostication has gained prominence.…”

Section: Introductionmentioning

confidence: 99%

Heterogeneity and molecular landscape of melanoma: implications for targeted therapy

Beigi,

Lanjanian,

Fayazi

et al. 2024

Mol Biomed

View full text Add to dashboard Cite

Uveal cancer (UM) offers a complex molecular landscape characterized by substantial heterogeneity, both on the genetic and epigenetic levels. This heterogeneity plays a critical position in shaping the behavior and response to therapy for this uncommon ocular malignancy. Targeted treatments with gene-specific therapeutic molecules may prove useful in overcoming radiation resistance, however, the diverse molecular makeups of UM call for a patient-specific approach in therapy procedures. We need to understand the intricate molecular landscape of UM to develop targeted treatments customized to each patient's specific genetic mutations. One of the promising approaches is using liquid biopsies, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), for detecting and monitoring the disease at the early stages. These non-invasive methods can help us identify the most effective treatment strategies for each patient. Single-cellular is a brand-new analysis platform that gives treasured insights into diagnosis, prognosis, and remedy. The incorporation of this data with known clinical and genomics information will give a better understanding of the complicated molecular mechanisms that UM diseases exploit. In this review, we focused on the heterogeneity and molecular panorama of UM, and to achieve this goal, the authors conducted an exhaustive literature evaluation spanning 1998 to 2023, using keywords like "uveal melanoma, “heterogeneity”. “Targeted therapies”," "CTCs," and "single-cellular analysis".

show abstract

“… 1 – 3 Recent data has indicated that prognostication of uveal melanoma depends heavily on the tumor genetic profile 4 – 23 and tumor size, 8 , 10 , 15 , 22 more so than the American Joint Committee on Cancer classification. 9 , 20 , 21 …”

mentioning

confidence: 99%

Conditional Metastasis of Uveal Melanoma in 8091 Patients over Half-Century (51 Years) by Age Group: Assessing the Entire Population and the Extremes of Age

Shields

Samuelson

et al. 2023

Invest. Ophthalmol. Vis. Sci.

Self Cite

View full text Add to dashboard Cite

Purpose To evaluate cumulative incidence of metastasis at specific timepoints after treatment of uveal melanoma in a large cohort of patients and to provide comparison of conditional outcomes in the youngest and oldest cohorts (extremes of age). Methods Retrospective analysis of 8091 consecutive patients with uveal melanoma at a single center over a 51-year period. The patients were categorized by age at presentation (0–29 years [n = 348, 4%], 30–59 years [n = 3859, 48%], 60–79 years [n = 3425, 42%], 80 to 99 years [n = 459, 6%]) and evaluated for nonconditional (from presentation date) and conditional (from specific timepoints after presentation) cumulative incidence of metastasis at five, 10, 20, and 30 years. Results For the entire population of 8091 patients, five-year/10-year/20-year/30-year nonconditional cumulative incidence of metastasis was 15%/23%/32%/36%, and the conditional incidence improved to 6%/15%/25%/30% for patients who did not develop metastasis in the first three years. For the extremes of age (0–29 years and 80–99 years), the nonconditional cumulative incidence of metastasis revealed the younger cohort with superior outcomes at 8%/15%/19%/27% and 21%/29%/29%/29%, respectively ( P < 0.001). The conditional incidence (at one-year and two-year timepoints with metastasis-free survival) showed persistent superior younger cohort survival ( P < 0.001, P = 0.001), but no further benefit for patients with three-year metastasis-free survival at 4%/12%/16%/24% and 7%/18%/18%/18%, respectively ( P = 0.09). Conclusions Non-conditional metastasis-free survival analysis for patients with uveal melanoma revealed the youngest cohort to have significantly better survival than the oldest cohort, and this persisted into one-year and two-year conditional metastasis-free survival but diminished at the three-year conditional timepoint.

show abstract

A prognostic classification system for uveal melanoma based on a combination of patient age and sex, the American Joint Committee on Cancer and the Cancer Genome Atlas models

Cited by 13 publications

References 67 publications

Pathological and Molecular Diagnosis of Uveal Melanoma

Pathological and Molecular Diagnosis of Uveal Melanoma

Heterogeneity and molecular landscape of melanoma: implications for targeted therapy

Conditional Metastasis of Uveal Melanoma in 8091 Patients over Half-Century (51 Years) by Age Group: Assessing the Entire Population and the Extremes of Age

Contact Info

Product

Resources

About